Efficacy of ixazomib for the treatment of relapsed/refractory multiple myeloma: A protocol of systematic review and meta-analysis.

Abstract

BACKGROUND:

Over the past years, ixazomib has been increasingly explored for the treatment of relapsed/refractory multiple myeloma (RRMM). However, its results are still contradictory. This study will explore the efficacy and safety of ixazomib for patients with RRMM.

METHODS:

A systematic records search of Cochrane Library, PUBMED, EMBASE, CINAHL, ACMD, PsycINFO, WANGFANG, and China National Knowledge Infrastructure will be carried out from their origin to March 31, 2020 with no limitations of language and publication status. Trials will be selected by titles/abstracts, and full manuscripts by 2 independent authors. Data collection will be carried out from eligible trials based on the previous designed criteria. Study quality will be checked using Cochrane risk of bias, and statistical analysis will be administered by RevMan 5.3 software.

RESULTS:

This study will summarize the current high-quality trials investigating the efficacy and safety of ixazomib for the treatment of patients with RRMM.

CONCLUSION:

The results of this study may provide convinced evidence on the evidence-based medicine level, and guidance for clinical practice and future studies.

INPLASY REGISTRATION NUMBER:

INPLASY202040027.

• Authors: Zhi Li, Shu-Li Guo, Wan-Li Wang
• Journal: Medicine (Medicine (Baltimore)) Vol. 99 Issue 20 Pg. e20211 (May 2020) ISSN: 1536-5964 [Electronic] United States
• PMID: 32443346 (Publication Type: Journal Article)

Chemical References

• Boron Compounds
• ixazomib
• Glycine

Topics

• Boron Compounds (standards, therapeutic use)
• Clinical Protocols
• Glycine (analogs & derivatives, standards, therapeutic use)
• Humans
• Multiple Myeloma (drug therapy)
• Neoplasm Recurrence, Local (drug therapy)
• Treatment Outcome